ASTCT Supports the FDA’s Approval of Earlier Use of CAR T-Cell Therapy for Multiple Myeloma
The Food and Drug Administration approves CAR T-Cell therapy Carvykti® as a second-line treatment and the CAR T-Cell therapy Abecma® as a third-line treatment for...
ASTCT, AACI, and ACCC Launch RECUR Initiative to Enhance Patient Access to CAR T Therapy
The American Society for Transplantation and Cellular Therapy (ASTCT), the Association of American Cancer Institutes (AACI), and the Association of Community Cancer Centers (ACCC) recently...